The 340B drug discount program is at a crossroads. What's next?

Wednesday, September 15, at 1:00 p.m. ET / 10:00 a.m. PT

To advocates, this program supports safety net hospitals. Critics say some game the system.

As the Biden administration takes control, STAT looks at what's next for this political football in a two part discussion.


Part 1: A Q&A with Robert Charrow

  • Robert Charrow, senior chair – health care and FDA practice, Greenberg Traurig
  • Rachel Cohrs, Washington correspondent, STAT (moderator)

Part 2: A stakeholder panel discussion

  • Ted Okon, MBA, executive director, Community Oncology Alliance
  • Maureen Testoni, president and chief executive officer, 340B Health
  • Vacheria Tutson, Esq., director, regulatory affairs, National Association of Community Health Centers
  • Sylvia Yu, senior counsel for federal programs, PhRMA
  • Rachel Cohrs, Washington correspondent, STAT (moderator)